Lb Pharmaceuticals (LBRX) Total Non-Current Liabilities (2024 - 2026)

Lb Pharmaceuticals' Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $13.6 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $13.6 million (changed N/A YoY), while the FY2025 annual figure was $10.3 million, down 9.22% from the prior year.
• Total Non-Current Liabilities was $13.6 million for Q1 2026 at Lb Pharmaceuticals, up from $10.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $13.6 million in Q1 2026 to a low of $9.6 million in Q3 2025.
• Historically, Total Non-Current Liabilities has averaged $11.2 million across 3 years, with a median of $10.8 million in 2024.
• Biggest YoY gain for Total Non-Current Liabilities was 9.22% in 2025; the steepest drop was 9.22% in 2025.
• A 3-year view of Total Non-Current Liabilities shows it stood at $11.3 million in 2024, then slipped by 9.22% to $10.3 million in 2025, then soared by 32.73% to $13.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $13.6 million (Q1 2026), $10.3 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.